Diabetes treatment should be effective and cost-effective. HbA1c-associated complications are costly. Would patient-centered care be more (cost-) effective if it was targeted to patients within specific HbA1c ranges?
Annabelle S Slingerland, William H Herman, William K Redekop, Rob F Dijkstra, J Wouter Jukema, Louis W Niessen
Research output: Contribution to journal › Article